Zentalis Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on discovering and developing novel therapeutics for oncology. Its lead product candidate is azenosertib an oral small molecule inhibitor of the WEE1 kinase. The company aims to bring azenosertib to patients with ovarian cancer and other solid tumor types.

Zentalis Pharmaceuticals, Inc. currently does not have product sales and generates revenue primarily from collaboration agreements and licensing arrangements. The company has previously entered into development collaborations with Pfizer GSK and Dana Farber Cancer Institute which have provided funding and have now concluded. Going forward Zentalis may seek new partnerships and may also raise capital through public or private offerings to support its research and development activities.

Zentalis Pharmaceuticals, Inc. operates in the competitive field of oncology drug development where several companies are pursuing WEE1 targeted therapies. Competitors include Debiopharm with its Debio 0123 molecule Bristol Myers Squibb with BMS 986463 Aprea Therapeutics with APR 1051 Schrödinger with SGR 3515 Acrivon Therapeutics with ACR 2316 Impact Therapeutics with IMP7068 Shouyao Holdings with SY 4835 WuXi AppTec with SC0191 and Wigen Biomedicine with WJB001. Zentalis differentiates itself by focusing on a biomarker driven approach using Cyclin E1 expression to identify patients most likely to respond to azenosertib. The company has received Fast Track designation from the FDA for azenosertib in platinum resistant ovarian cancer which may accelerate development and review timelines. These factors together with its oral formulation and manageable safety profile give Zentalis a competitive edge in the crowded oncology market.

Zentalis Pharmaceuticals, Inc. ultimately intends to serve patients diagnosed with ovarian cancer and other solid tumors who are candidates for its investigational therapy. The company’s customers will include hospitals oncology clinics and healthcare providers that administer cancer treatments. Additionally Zentalis may work with diagnostic partners to provide companion diagnostic tests that identify Cyclin E1 positive patients.